首页 > 会议日程详情
2025-06-15 星期日
10:10-11:00 【B座-4层-402】

Session III
主持人

谷欣权 

梅红兵 

曹凤宏 

吴松 

多发肾肿瘤极限保肾手术的思考与探索
Updated results from a phase II study of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC).
Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer
PSMA PETCT在转移性去势抵抗性前列腺癌患者二次活检中的探索与应用

邵渊  10:40-10:50

[专题报告]

How low do you need to go? Association between various prostate-specific antigen (PSA) response measures and clinical outcomes in metastatic castration‑sensitive prostate cancer (mCSPC) in the Veteran Health Administration (VHA) data